Summary of Key Points from the Conference Call Industry Overview - The pharmaceutical industry is experiencing sustained growth, particularly in the innovative drug and device sectors, with leading companies such as WuXi AppTec, Tigermed, United Imaging, and Lepu Medical being highlighted as key players [1][2] - The consumer healthcare sector is expected to recover to positive growth by 2026 after a period of price stabilization, with a focus on underperforming segments like dental and ophthalmic products [1][5] - The brain-computer interface industry is at a critical juncture with technological breakthroughs and clinical validations, supported by policies and the production plans of companies like Neuralink, presenting significant investment opportunities [1][15] Company Recommendations - Recommended companies in the A-share market include: - Heng Rui Medicine - Kelun Pharmaceutical - East China Pharmaceutical - Enhua Pharmaceutical - Teva Biopharmaceuticals - Jingxin Pharmaceutical - Yifan Biopharmaceuticals - WuXi AppTec - Tigermed - Lepu Medical - United Imaging - In the Hong Kong market, recommended companies include: - Hansoh Pharmaceutical - 3SBio - Kelun Biotech - Kintor Pharmaceutical - Yifan Biopharmaceuticals - BeiGene [3] Market Trends and Performance Expectations - The overall strategy for the pharmaceutical sector remains unchanged, with a focus on innovative drugs and devices, expecting a positive shift in performance in Q1 2026 despite a downturn in 2025 [2] - The blood products sector faced significant pressure in 2024, but recovery is anticipated in 2025 due to new product launches [6] - The Chinese medical device market is expected to see optimistic revenue growth in 2026, driven by new product launches and successful bidding processes [11] - United Imaging is projected to have a strong market performance in 2026, benefiting from improved bidding data and expected overseas growth of over 30% [3][12] Specific Sector Insights - The innovative drug sector is actively evolving globally, with China significantly participating in the global R&D landscape, particularly in oncology and metabolic disease treatments [4] - The weight loss and metabolic drug sector is seeing numerous catalysts, with companies like Heng Rui and BoRui focusing on long-acting injection formulations and oral lipid formulations [1][17] - In the autoimmune sector, companies like Yifan, Haizhi, and Kangnuo are highlighted for their oral drugs and long-acting bispecific antibodies, with significant collaborations enhancing their market potential [1][19] Additional Considerations - The pharmacy sector is recommended to focus on leading companies like Yifeng, which is pursuing growth through mergers and acquisitions [7] - The microelectrophysiology market is expected to accelerate revenue growth in 2026 due to the launch of new products and successful bidding processes [10] - The impact of medical insurance negotiations on the GLP-1 market is crucial for increasing penetration rates, with positive policy support for innovative drug development [21]

Investment Rating - The report assigns an "Overweight" rating for the healthcare service industry [3]. Core Insights - The healthcare insurance fund's income showed stable growth in 2025, with a cumulative income of CNY 26,320.68 billion from January to November, reflecting a year-on-year increase of 2.9%. The income from urban employee insurance reached CNY 16,643.79 billion (+5.7%), while the income from rural resident insurance decreased by 1.6% to CNY 9,676.89 billion [2][4]. - The cumulative expenditure of the healthcare insurance fund from January to November was CNY 21,100.46 billion, marking a year-on-year increase of 0.5%. Urban employee insurance expenditure was CNY 12,033.33 billion (+2.4%), and rural resident insurance expenditure was CNY 9,067.14 billion (-1.9%) [4][9]. - The cumulative surplus of the healthcare insurance fund as of November 2025 was CNY 5,220.22 billion, with a surplus rate of 19.8%. The urban employee insurance fund had a surplus of CNY 4,610.46 billion (27.7%), while the rural resident insurance fund had a surplus of CNY 609.75 billion (6.3%) [4][9]. Summary by Sections Income and Expenditure - The healthcare insurance fund's income in November 2025 was CNY 2,800.58 billion, showing a month-on-month increase of 11.2%. The urban employee insurance fund's income was CNY 1,492.65 billion (+4.4%), and the rural resident insurance fund's income was CNY 1,307.92 billion (+20.1%) [9]. - The expenditure for November 2025 was CNY 2,064.22 billion, reflecting a year-on-year increase of 13.0%. Urban employee insurance expenditure was CNY 1,093.39 billion (+3.9%), and rural resident insurance expenditure was CNY 970.85 billion (+25.3%) [9]. Fiscal Health Expenditure - Cumulative health expenditure from the general public budget was CNY 18,687 billion from January to November 2025, with a year-on-year growth of 4.7%. The expenditure in November alone was CNY 1,810 billion, marking a significant increase of 32.5% [7][8].

Investment Rating - The report maintains an "Overweight" rating for the innovative pharmaceutical and medical device industry chain [4][8]. Core Viewpoints - The report continues to recommend the innovative pharmaceutical and medical device industry chain, highlighting a selection of A-share and H-share stocks with an "Overweight" rating [2][8][11]. - The performance of the pharmaceutical sector in December 2025 was weaker than the broader market, with the SW Pharmaceutical Biotechnology index declining by 4.1% compared to a 2.1% increase in the Shanghai Composite Index [18][30]. - The report notes that the premium level of the pharmaceutical sector relative to the entire A-share market is currently at a normal level, with a relative premium rate of 63.2% as of December 31, 2025 [29][32]. Summary by Sections A-Share Recommendations - The report lists the following A-share stocks with an "Overweight" rating: - 恒瑞医药 (Hengrui Medicine) - 科伦药业 (Kelun Pharmaceutical) - 华东医药 (East China Pharmaceutical) - 恩华药业 (Enhua Pharmaceutical) - 特宝生物 (Tebao Biological) - 京新药业 (Jingxin Pharmaceutical) - 益方生物 (Yifang Biological) - 药明康德 (WuXi AppTec) - 泰格医药 (Tigermed) - 乐普医疗 (Lepu Medical) - 联影医疗 (United Imaging) - 微电生理 (Microelectrophysiology) [8][9]. H-Share Recommendations - The report maintains an "Overweight" rating for the following H-share stocks: - 翰森制药 (Hansoh Pharmaceutical) - 三生制药 (3SBio) - 科伦博泰生物 (Kelun-Botai Biological) - 康方生物 (CanSino Biologics) - 映恩生物 (InnoCare Pharma) - 百济神州 (BeiGene) [11][12]. Performance Analysis - The report indicates that the 国泰海通医药 monthly portfolio outperformed the pharmaceutical index in December 2025, with an average decline of 1.8% compared to a 3.9% decline in the overall pharmaceutical index [14][15]. - The report highlights the best-performing stocks in December 2025, with 泰格医药 (Tigermed) increasing by 11.2%, 特宝生物 (Tebao Biological) by 7.5%, and 惠泰医疗 (Huitai Medical) by 3.9% [15][18].

Investment Rating - The report maintains an "Outperform" rating for several companies in the pharmaceutical sector, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [5][6]. Core Insights - The report emphasizes the high prosperity in innovative drugs and continues to recommend companies with promising pipelines and performance growth in the Biopharma/Biotech sector, maintaining an "Outperform" rating for Innovent Biologics, WuXi XDC Cayman, and others [5][23]. - It highlights the performance of the A-Shares pharmaceutical sector, which underperformed the market, with the SW Pharma & Bio index falling by 0.2% while the SHCOMP rose by 1.9% [7][18]. - The report notes that the premium level of the pharmaceutical sector relative to all A-Shares is currently at a normal level of 66.7% as of December 26, 2025 [13][17]. Summary by Sections 1. Continued Recommendation for Innovative Drugs and Industry Chain - The report continues to recommend innovative drugs and the associated industry chain, highlighting the high demand and potential for revaluation in the pharmaceutical sector [5][23]. - Specific companies recommended include Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical, all rated as "Outperform" [5][6]. 2. A-Shares Pharmaceutical Sector Performance - In the fourth week of December 2025, the A-Shares pharmaceutical sector underperformed the broader market, with a decline of 0.2% compared to a 1.9% increase in the SHCOMP index [7][18]. - The best-performing sub-sectors included chemical raw materials (+2.0%) and medical equipment (+0.1%), while biological products saw a slight decline of -0.1% [9][18]. 3. Hong Kong and U.S. Market Performance - The Hong Kong pharmaceutical sector also underperformed, with the Hang Seng Healthcare index down by 1.8% and the Hang Seng Biotechnology index down by 2.3% [18]. - In contrast, the U.S. pharmaceutical sector performed similarly to the market, with the S&P Healthcare Select Sector increasing by 1.0% [18].

Investment Rating - The report maintains a focus on the innovative drug and medical device industry chain, indicating a high level of interest in this sector [1][6]. Core Insights - The innovative drug sector is experiencing high prosperity, with a recommendation to pay attention to pharmaceutical companies that are likely to see a revaluation of their value, such as Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [6][25]. - The report highlights the Biopharma/Biotech sector, which is expected to see performance improvements as innovative pipelines are realized, with companies like Innovent Biologics, BeiGene, and others being of particular interest [6][25]. - Attention is also drawn to CXO and upstream companies benefiting from innovation, including WuXi AppTec and WuXi Biologics [6][25]. - The report emphasizes the potential recovery of leading medical device companies such as United Imaging Healthcare and Lepu Medical [6][25]. Summary by Sections A-Shares Performance - In the third week of December 2025, the A-share pharmaceutical sector performed similarly to the overall market, with the Shanghai Composite Index rising by 0.03% and the SW Pharma and Biotech index falling by 0.1%, ranking 19th among Shenwan primary industries [8][10]. - Sub-sectors that performed relatively well included pharmaceutical commerce (+4.9%), medical equipment (+1.2%), and medical services (+0.5%) [10][25]. - Notable individual stock performances included Anhui Huaren Health Pharmaceutical Co., Ltd. (+55.9%), Luyan Pharma (+36.8%), and ShuYu Civilian (+35.7%) [13][25]. Hong Kong and U.S. Market Performance - The Hong Kong pharmaceutical sector underperformed the market, with the Hang Seng Healthcare index down by 1.8% and the Hang Seng Index down by 1.1% [19][25]. - In contrast, the U.S. pharmaceutical sector outperformed the market, with the S&P Healthcare Select Sector rising by 0.6% compared to the S&P 500's 0.1% increase [19][25].

Investment Rating - The report maintains an "Overweight" rating for the innovative pharmaceutical and medical device industry chain [3][5][6]. Core Insights - The report emphasizes the continuous recommendation of innovative drugs and medical devices, highlighting the high growth potential in the innovative pharmaceutical sector. It maintains "Overweight" ratings for companies such as Heng Rui Medicine, Hansoh Pharmaceutical, and others, indicating a potential for value re-evaluation [3][5]. - The report notes that the National Medical Insurance Administration has officially announced the 2025 medical insurance drug catalog, which includes 114 new drugs, 50 of which are first-class innovative drugs. This adjustment is seen as a validation of the support for innovation in the healthcare sector [3][5]. - The A-share pharmaceutical sector underperformed the broader market in the second week of December 2025, with the SW Pharmaceutical Biotechnology index declining by 1.0% compared to a 0.3% drop in the Shanghai Composite Index [7][18]. Summary by Sections Section 1: Continuous Recommendation of Innovative Drugs and Medical Devices - The report highlights the sustained recommendation of innovative drugs and medical devices, with a focus on companies that are expected to see performance growth and value re-evaluation [5][6]. Section 2: A-share Pharmaceutical Sector Performance - In the second week of December 2025, the A-share pharmaceutical sector's performance was weaker than the overall market, ranking 16th among the primary industries [7][18]. Section 3: Hong Kong and US Market Performance - The report indicates that the Hong Kong pharmaceutical sector also underperformed, while the US pharmaceutical sector showed stronger performance compared to the broader market [18].

Group 1: Style Rotation Insights - The Q4 style rotation model indicates signals for small-cap and growth stocks [2][3] - The dual-driven rotation strategy for Q4 has a composite score of -1, predicting a focus on small-cap stocks [3] - The value-growth style rotation model shows a composite score of -3, suggesting a preference for growth stocks [4] Group 2: Industry Rotation Analysis - In November, the composite factor strategy yielded an excess return of -0.58%, while the single-factor long strategy had an excess return of -0.83% [4] - For December, the recommended long industries based on single-factor strategies include banking, construction, non-bank financials, and electric equipment & new energy [4] - The composite factor strategy recommends long positions in telecommunications, comprehensive finance, computers, electric equipment & new energy, and utilities [4] Group 3: Pharmaceutical Sector Performance - In November 2025, the pharmaceutical sector underperformed the broader market, with the SW pharmaceutical and biological index declining by 3.6% compared to a 1.7% drop in the Shanghai Composite Index [7] - The relative premium level of the pharmaceutical sector is currently at 72.6%, indicating a normal valuation level compared to all A-shares [7] - In the Hong Kong market, the pharmaceutical sector performed similarly to the market, with the Hang Seng Medical Care index at -0.1% and the biotechnology sector at +0.4% [7] Group 4: U.S. Pharmaceutical Market Trends - In November 2025, the U.S. pharmaceutical sector outperformed the broader market, with the S&P Healthcare Select Sector Index rising by 9.1% compared to a 0.1% increase in the S&P 500 [8] - Notable gainers in the S&P 500 healthcare component included Eli Lilly (+25%) and Solventum (+23%) [8]

Summary of Conference Call Records Industry Overview - The pharmaceutical sector underperformed the broader market in November, with pharmaceutical commerce, traditional Chinese medicine, and raw materials performing relatively well [1][5] - The S&P Healthcare Select Sector Index in the US rose by 9.1%, outperforming the S&P 500 Index by 0.1% [5] Key Companies and Recommendations New Additions to Investment Portfolio - **Jin Xin Pharmaceutical**: Added due to its low valuation and stable core business; its LPA project ranks among the top two in China, expected to act as a catalyst [1][6] - **Yi Fang Bio**: Stock price has reached a low point; TIKTOO product is expected to have potential authorization in the next six months, with similar product data from Takeda acting as a catalyst [1][7] - **Te Bao Bio**: Main product Pegasys for hepatitis B has received approval, with new patient numbers increasing; expected to continue high growth next year [1][8][9] Continued Recommendations - **Hengrui Medicine**: Strong R&D pipeline and favorable procurement situation; R&D Day on December 5 is a key event to watch [1][10] - **Medical Device Leaders**: Long-term investment value due to stable competitive landscape and recovery in terminal bidding; many companies reported revenue turning points in Q3 [1][11] Market Trends and Projections - The medical device industry is expected to see a recovery trend in Q4 2025 and 2026, with strong performance in neuro-intervention and neurosurgery sectors [1][12] - The IVD industry may face volume and price pressures in 2025 but is expected to see a turning point in 2026 [1][12][13] Competitive Landscape - China's medical device market is gaining global competitiveness due to advantages in engineering, industrial clusters, supply chains, and clinical resources [1][14] - Despite complexities, Chinese medical devices are competitive globally due to cost-effectiveness; leading companies are increasing overseas revenue [1][14] Individual Company Insights - **Kelong Pharmaceutical**: Faced challenges due to procurement price reductions but is expected to stabilize with rising demand for large-volume infusions [1][16] - **BeiGene**: Anticipated to achieve profitability for the first time, with strong sales performance from its drug Zebrutinib [1][16] Investment Recommendations - Recommended stocks include **United Imaging**, **Lepu Medical**, **Hui Tai**, **Chun Li**, and **New Industry** in the IVD sector [1][15] - **United Imaging**: Expected to continue high growth with new product contributions [1][15] - **Lepu Medical**: Stable core business with growth potential in new sectors [1][15] Future Catalysts - TIK2 inhibitors are expected to show potential in various indications, with significant data releases anticipated [1][18] - Jin Xin Pharmaceutical has completed Phase I clinical trials with satisfactory results, indicating strong potential in the cardiovascular field [1][20][21] Conclusion - The pharmaceutical and medical device sectors are poised for recovery, with specific companies showing strong potential for growth and investment opportunities in the coming years.

Investment Rating - The report maintains an "Outperform" rating for A-Shares including Jiangsu Heng Rui Medicine, Sichuan Kelun Pharmaceutical, Huadong Medicine, Jiangsu Nhwa Pharmaceutical, Xiamen Amoytop Biotech, Zhejiang Jingxin Pharmaceutical, Innovent Biologics, WuXi AppTec, Hangzhou Tigermed Consulting, Lepu Medical, and APT Medical [2][4][29] - The report also maintains an "Outperform" rating for H-Shares including Hansoh Pharmaceutical Group, 3SBio, PATEO, Akeso, and related targets such as Innovent Biologics and WuXi AppTec (H-Shares) [2][7][29] Core Insights - The report continues to recommend the innovative drug and device industry chain [1][2] - In November 2025, the pharmaceutical sector underperformed the broader market, with the SW Pharma Bio index falling by 3.6% compared to a 1.7% drop in the SHCOMP [2][10] - The premium of the pharmaceutical sector to all A-Shares is currently at a normal level of 72.6% as of the end of November 2025 [17][22] Summary by Sections A-Shares Performance - The report highlights the A-Shares that are recommended for investment, maintaining an "Outperform" rating for several companies, including Jiangsu Heng Rui Medicine and Sichuan Kelun Pharmaceutical, among others [4][5] - The report notes that the pharmaceutical sector's performance was ranked 23rd among Shenwan's first-level industries in November 2025 [10][12] H-Shares Performance - The report indicates that the H-Shares pharmaceutical sector performed in line with the market, with the Hang Seng Healthcare index down by 0.1% and the biotech sector up by 0.4% in November 2025 [2][23] - Top gainers in the H-Shares market included Laekna, Inc. (+40%) and Clover Biopharmaceuticals, Ltd. (+22%) [23] U.S. Market Performance - The U.S. pharmaceutical sector outperformed the broader market in November 2025, with the S&P Healthcare Select Sector rising by 9.1% compared to a 0.1% increase in the S&P 500 [23]

Investment Rating - The report maintains an "Overweight" rating for the innovative pharmaceutical and medical device industry chain [3][5]. Core Viewpoints - The innovative pharmaceutical sector is experiencing high prosperity, with a recommendation for companies like Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi Pharmaceutical, Kelun Pharmaceutical, and Enhua Pharmaceutical to maintain an "Overweight" rating. The report also suggests that Biopharma/Biotech companies such as Kelun Biotech, BeiGene, Baillie Gifford, Yimeng Biotech, Jingxin Pharmaceutical, Teva Biotech, WuXi Biologics, and Ailisi should also be rated "Overweight" as their innovative pipelines are gradually being realized and their performance is entering a growth phase. Additionally, it recommends CXO and upstream pharmaceutical companies like Haoyuan Medicine, Baipusais, WuXi AppTec, WuXi AppTec, and Tigermed to maintain an "Overweight" rating. The report highlights leading medical device companies such as United Imaging, Lepu Medical, Spring Medical, and Huatai Medical as having potential for recovery, also maintaining an "Overweight" rating [5][6]. Summary by Sections - **A-Share Market Performance**: In the third week of November 2025, the A-share pharmaceutical sector underperformed the broader market, with the Shanghai Composite Index falling by 3.9% and the SW Pharmaceutical and Biological Index declining by 6.9%, ranking 23rd among Shenwan's primary industries [7][9]. - **Hong Kong and US Market Performance**: The Hong Kong pharmaceutical sector also underperformed, with the Hang Seng Healthcare Index and the Hong Kong Biotechnology Index both down by 7.5%, while the US healthcare sector outperformed, with the S&P Healthcare Select Sector Index rising by 1.8% [17]. - **Valuation Metrics**: As of November 21, 2025, the pharmaceutical sector's premium level relative to the entire A-share market is at a normal level, with a current relative premium rate of 71.8% [13][16].